1 LMC Diabetes & Endocrinology, Toronto, Canada.
2 School of Kinesiology and Health Science, York University, Toronto, Canada.
Diabetes Technol Ther. 2019 May;21(5):286-294. doi: 10.1089/dia.2018.0387. Epub 2019 Apr 24.
This study investigated the accuracy of real-time continuous glucose monitoring (rtCGM) during high intensity interval training (HIIT) in patients with type 1 diabetes (T1D). Seventeen participants with T1D, using multiple daily injections (MDI) with basal insulin glargine 300 U/mL (Gla-300), completed four fasted HIIT sessions over 4 weeks while wearing a Dexcom rtCGM G4 Platinum system. Each exercise consisted of high intensity interval cycling and multimodal training over 25 min. Reference venous plasma glucose (PG) was measured at 60- and 10-min before exercise (Stage 1), every 10 min during exercise and then every 15 min until 180 min after the end of exercise (Stage 2: during exercise and 45-min early recovery; Stage 3: 45 min to 3 h after the end of exercise); and at 6-, 10-, and 13-h postexercise (Stage 4). In the 64 HIIT sessions that resulted in hyperglycemia, PG increased 90.0 ± 32.4 mg/dL (mean ± standard deviation), peaking at 68.0 ± 18.4 min from the start of HIIT. Mean absolute relative difference was highest during exercise and early recovery (Stage 2) at 17.8%, versus Stage 1 (10.4%), Stage 3 (10.6%), and Stage 4 (11.5%) ( < 0.001). During Stage 2, rtCGM showed a significant negative bias of 35.3 mg/dL ( < 0.001) compared to reference glucose. Lag time to reach the half-maximal glucose rise was 35 min in rtCGM versus PG. The Surveillance Error Grid found that in Stage 2, only 65.5% of paired values were in the no-risk zone and the %15/15 was 50%, significantly lower than the other stages ( < 0.001). During HIIT and early recovery, there is an increase in lag time and a related decline in accuracy of Dexcom rtCGM G4, compared to pre-exercise and later recovery, in patients with T1D using MDI.
本研究旨在探讨实时连续血糖监测(rtCGM)在 1 型糖尿病(T1D)患者高强度间歇训练(HIIT)中的准确性。17 名接受多次皮下注射(MDI)联合基础胰岛素甘精 300U/mL(Gla-300)治疗的 T1D 患者,在佩戴 Dexcom rtCGM G4 铂金系统的情况下,在 4 周内完成了 4 次禁食 HIIT 训练。每次运动均包括高强度间歇骑行和多模式训练,持续 25 分钟。在运动前 60-10 分钟(第 1 阶段)、运动期间每 10 分钟、运动结束后 180 分钟内每 15 分钟(第 2 阶段:运动和 45 分钟早期恢复;第 3 阶段:运动结束后 45 分钟至 3 小时)以及运动后 6、10 和 13 小时(第 4 阶段)测量参考静脉血浆血糖(PG)。在导致高血糖的 64 次 HIIT 训练中,PG 升高 90.0±32.4mg/dL(平均值±标准差),在 HIIT 开始后 68.0±18.4 分钟达到峰值。平均绝对相对差异在运动和早期恢复期间(第 2 阶段)最高,为 17.8%,而在第 1 阶段(10.4%)、第 3 阶段(10.6%)和第 4 阶段(11.5%)(<0.001)。在第 2 阶段,与参考葡萄糖相比,rtCGM 显示出 35.3mg/dL(<0.001)的显著负偏倚。达到葡萄糖半最大升高的滞后时间在 rtCGM 中为 35 分钟,而在 PG 中为 35 分钟。监测误差网格发现,在第 2 阶段,只有 65.5%的配对值处于无风险区,%15/15 为 50%,显著低于其他阶段(<0.001)。在 T1D 患者中,使用 MDI 时,与运动前和后期恢复相比,Dexcom rtCGM G4 在 HIIT 和早期恢复期间的滞后时间增加,准确性下降。